GlassScriptPhysician profile
Andrew Hale
NPI 1851786412
$8,626.05
in general payments reported to CMS, 2019-2025
35 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $1,443 · 2021: $1,889 · 2022: $954 · 2023: $972 · 2024: $1,173 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,377.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,798.52 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Gallant |
| Boston Scientific Corporation | $927.29 | 2019-2025 | General - Therapies, Cds Broad Portfolio Offering, General - Crm_crm |
| Novartis Pharmaceuticals Corporation | $853.52 | 2021-2025 | |
| Abiomed | $780.77 | 2023-2025 | Impella |
| Pfizer INC. | $434.55 | 2019-2024 | |
| Heartflow, INC. | $379.07 | 2023-2024 | Ffrct |
| Edwards Lifesciences Corporation | $289.83 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $246.54 | 2021-2023 | Xarelto |
| Elutia, INC. | $240.20 | 2022 | |
| Impulse Dynamics (USA) INC. | $210.17 | 2023-2025 | Optimizer, Optimizer |
| Ge Healthcare | $201.61 | 2022-2024 | |
| Philips North America LLC | $140.61 | 2021-2025 | Mcot |
| E.R. Squibb & Sons, L.L.C. | $130.29 | 2023-2025 | Camzyos, Eliquis |
| Atricure, INC. | $108.40 | 2020-2023 | |
| Baxter Healthcare | $104.28 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Floseal |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $99.00 | 2021 | |
| Angiodynamics, INC. | $74.49 | 2022-2025 | Alphavac |
| Medtronic Vascular, INC. | $73.77 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $63.14 | 2019-2020 | |
| Amgen INC. | $59.34 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $50.14 | 2022-2023 | Verquvo |
| Chiesi USA, INC. | $40.59 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.68 | 2023-2024 | Jardiance |
| Polynovo North America LLC | $34.01 | 2024 | Novosorb Btm |
| Cordis US Corp. | $33.94 | 2024 | Radial 360, Mynxgrip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.09 | 2022-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $29.21 | 2021-2025 | |
| Depuy Synthes Sales INC. | $24.55 | 2025 | |
| Amarin Pharma, INC. | $21.49 | 2021 | |
| Esperion Therapeutics, INC. | $19.99 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $18.83 | 2019 | |
| Novo Nordisk INC | $17.74 | 2024 | Ozempic |
| Aegerion Pharmaceuticals, INC. | $17.61 | 2019 | |
| Cvrx, INC. | $16.58 | 2023 | Barostim Neo System |
| Irhythm Technologies, INC. | $16.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.